openPR Logo
Press release

Lumakras Drug Clinical Insight and Sales Forecast 2026

05-20-2022 02:44 PM CET | Health & Medicine

Press release from: Kuick Resarch

"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights:

* NSCLC Targeting Lumakras Market Opportunity (US$ Million)
* Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
* Pharmacokinetics of Lumakras (Sotorasib)
* Dosage, Patent and Price Analysis
* Lumakras Ongoing Clinical Trials
* Global KRAS Protein Inhibitors Clinical Trials

Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase

The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management of cancer. Despite huge advancements in the field of cancer therapeutics, there has been no permanent cure of cancer till now. However, the advancement in the field of science and technology has led to the identification of potential targets which can be utilized in drug development process.

The identification of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene as well as its potential role in the pathogenesis and proliferation of cancer has shown to be boon in cancer therapeutics. The extensive research and development by the researchers has led to the discovery of novel KRAS inhibitors which are used in the management of rare ALK positive cancers. Till now, only one KRAS inhibitor has been approved for the management of non-small cell lung cancer.

Lumakras (Sotorasib) is first KRAS inhibitor developed by Amgen and was approved by FDA in May, 2021. Lumakras is a once-daily oral prescription medicine used to treat adults living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. The approval of Lumakras represents as one of the major revolution in the field of cancer treatment.

Owing to their favorable characteristics in management of NSCLC as well its high specificity and efficacy, it is expected that Lumakras market will witness high growth rates. AAs per report findings, it is expected that Lumakras market is expected to surpass US$ 1.5 Billion by 2026. This is due to the ability of Lumakras in overcoming the limitations of already conventional cancer therapies. Moreover, the drug Lumakras is not associated with side effects in comparison to conventional cancer treatments and also improved the survival rates in patients.

Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years. However, increasing initiatives by government and the pharmaceutical companies for the development of favorable reimbursement policies will help in lowering the cost of the therapy, thus reducing financial toxicity on patients.

The global Lumakras market will follow trajectory path during the forecast period owing to the single product approval. In addition to this, researchers are also evaluating the role of Lumakras in other solid tumors as well in combination of other immunotherapeutic drugs, which will drive the growth of market. North America particularly US is expected to dominate the global Lumakras market for next few years owing to increase in prevalence of non-small cell lung cancer and the presence of large pharmaceutical companies which actively indulge in research and development activities.

The report global Lumakras market contains information on the price, dosage and expected sales of the drug in different regions. In addition to this, it also provides information on the safety, efficacy, pharmacokinetics, and pharmacovigilance profile of Lumakras. The report also provides insights on the recent clinical trials undergoing with the drug and predict the future market of the drug at a global level.

Contact:

Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+919810410366
https://www.kuickresearch.com/

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lumakras Drug Clinical Insight and Sales Forecast 2026 here

News-ID: 2631531 • Views: 222

More Releases from Kuick Resarch

Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight
Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026
"Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026" Report highlights: * Europe Biosimilars Market Opportunity: > USD 10 Billion * Dosage and Pricing insight On Approved Biosimilars * Biosimilars for Cancers Accounts for > 20% Market * Biosimilars for Diabetes Accounts for > 5% Market * Biosimilars Approval and Commercialization by Country * Insight On Biosimilar Clinical Trials By Company, Indication and Phase: > 100 Biosimilars * Insight On Commercially available Biosimilars in Market:

All 5 Releases